 Distigmine bromide | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth, i.m. |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 4.65%[1] |
| Eliminationhalf-life | 65 h[1] |
| Excretion | renal[1] |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.036.360 |
| Chemical and physical data | |
| Formula | C22H32Br2N4O4 |
| Molar mass | 576.330 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Distigmine (asdistigmine bromide) is aparasympathomimetic. Distigmine is similar topyridostigmine andneostigmine but has a longer duration of action. It is available as tablets on prescription only. It is commonly used to treat various conditions, including myasthenia gravis and underactive bladder.[2] Distigmine has a greater risk of causingcholinergic crisis because of accumulation of the drug being more likely than with neostigmine or pyridostigmine and so distigmine is rarely used as a treatment for myasthenia gravis, unlike pyridostigmine and neostigmine.
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |